{
    "nct_id": "NCT05983276",
    "official_title": "Combination of the Hypomethylating Agent Decitabine and the Nuclear Export Receptor XPO-1 Inhibitor Selinexor to Reverse Platinum Resistance in Relapsed/Refractory Epithelial Ovarian Cancer",
    "inclusion_criteria": "* Participants must be greater than or equal to 18 years of age\n* Participants must have an Eastern Cooperative Oncology Group (ECOG) Performance Status PS less than or equal to 2.\n* Participants must have histological or cytological proven epithelial ovarian cancer, fallopian tube or primary peritoneal carcinoma with relapse or disease progression after prior treatment by exam, computed tomography (CT), PET/CT, or magnetic resonance imaging (MRI) may be enrolled. All cell types including clear cell carcinoma are eligible.\n* Participants must have failed or relapsed after a platinum and taxane containing combination\n* Participants must have adequate hepatic function\n* Participants must have adequate renal function\n* Participants must be able to swallow and retain oral medications\n* Participants must have measurable disease according to Gynecologic Cancer Intergroup CA125 criteria\n* Participants with stable (for 2 months or longer), treated (by radiotherapy) CNS metastases are eligible\n* Participants with active hepatitis B virus (Hep B) are allowed if antiviral therapy for hepatitis B has been given for greater than 8 weeks.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Participants must not have received Selinexor or another XPO1 inhibitor previously.\n* Participants must not have had any concurrent medical condition or disease (eg, uncontrolled active hypertension, uncontrolled active diabetes, active systemic infection, etc.)\n* Participants must not have uncontrolled active infection. Participants on prophylactic antibiotics or with a controlled infection within 1 week prior to C1D1 are acceptable.\n* Participants must not have known intolerance, hypersensitivity, or contraindication to platinum or taxane therapy\n* Participants must not have active, unstable cardiovascular function\n* Participants must not have myocardial infarction within 3 months prior to starting\n* Participants with untreated central nervous system (CNS) metastases are ineligible.\n* Participants must not have had prior chemotherapy or radiation therapy\n* Participants must not have DVT related to metastatic disease requiring ongoing anticoagulation.",
    "miscellaneous_criteria": ""
}